ClinicalTrials.gg
Active, not recruitingNCT00918775Updated Oct 6, 2026

Follow-up After Metastasectomy in Patients With Kidney Cancer

A Phase 2 interventional study of Follow-Up Care and Laboratory Biomarker Analysis in Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by M.D. Anderson Cancer Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center — 10 open to participants now, 25 under way, 1 of them phase 3. Carcinoma, Renal Cell · M.D. Anderson Cancer Center.

Enrollment
12th of 54
86 · median 43
Started
2009
the only one that year
Phase 2
33 of 56
5 open now
Primary completion
2026-12
later than 1 of 24 live
Registered
14th of 56
by date

Among the 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center, this one is the 12th largest by enrollment of the 54 interventional ones that give a count, is the only one that started in 2009, is one of 33 in phase 2, reaches primary completion later than 1 of the 24 other live ones, and was the 14th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

10 of the 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Carcinoma, Renal Cell by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This phase II trial studies the follow-up after metastasectomy in patients with kidney cancer. Following up patients' health condition after metastasectomy may help doctors to learn if the surgical removal of the primary tumor or the parts of the cancer that has spread to other parts of the body is a good method for treating patients who have kidney cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess the 24-week progression free/relapse free survival rate in patients undergoing metastasectomy for metastatic renal cell carcinoma (mRCC).

SECONDARY OBJECTIVES:

I. To evaluate progression free survival (PFS), relapse free survival (RFS) and overall survival (OS) in patients undergoing metastasectomy.

II. To evaluate tissue determinants predictive for resectability, PFS and OS in patients undergoing metastasectomy.

OUTLINE:

After metastasectomy, patients are followed up every 6 months for up to 5 years.

03

Conditions studied

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with or cytologically confirmed renal cell carcinoma (RCC)
  • Patients have clinical reasons for undergoing a surgical resection of tumor; there are two main categories of patients:

    • Patients with fully resectable disease as defined by lesions accessible by a surgeon during no more than two separate surgical sessions, and are expected to be rendered surgically no evidence of disease (NED)
    • Patients undergoing a noncurative procedure for relief of symptoms or for management of threatening lesions
  • Patients have been deemed resectable by the subspecialty surgeon involved in the patient's care
  • Patients must give written prior to initiation of therapy, in keeping with the policies of the institution; patients with a history of major psychiatric illness must be judged able to fully understand the nature of the study and the risks associated with the therapy; the only approved consent is attached to this protocol
  • Patients must have ability to comply with study and/or follow-up procedures
  • Members of all races and ethnic groups are eligible for this trial

Exclusion criteria

Exclusion Criteria:

  • Patients must not have active acute infections that could be worsened by surgery or interfere with this study
  • Patients must not have cardiovascular disease, or peripheral vascular disease that creates an unacceptably high operative risk
  • Patients must not have history of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates surgical resection, or render the subject at high risk from treatment complications
  • Patients must not have a history of uncontrolled severe depression
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Enrollment
86 participants (actual)

Study arms

  • Other
    Observational (follow-up)

    After metastasectomy, patients are followed up every 6 months for up to 5 years.

    Other: Follow-Up Care · Other: Laboratory Biomarker Analysis

Interventions

  • OtherFollow-Up Care

    Undergo follow-up

  • OtherLaboratory Biomarker Analysis

    Correlative studies

06

What researchers measure

Primary outcomes

  1. Binary indicator that the patient is alive with no evidence of disease progression (either progression or relapse) post surgery

    Assessed using a logistic regression model.

    Time frame: 24 weeks

Secondary outcomes

  1. Progression free survival (PFS)

    Time frame: Up to 5 years

  2. Overall survival (OS)

    Will be analyzed by Kaplan Meier plots and appropriate regression analyses using the vector of intervention indicators (ZD, ZE, ZI) as covariates, with the model determined by preliminary goodness-of-fit analyses.

    Time frame: Up to 5 years

  3. Disease free survival (DFS)

    Will be analyzed by Kaplan Meier plots and appropriate regression analyses using the vector of intervention indicators (ZD, ZE, ZI) as covariates, with the model determined by preliminary goodness-of-fit analyses.

    Time frame: Up to 5 years

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2009 (actual). Primary completion is estimated for Dec 2026, 210 months after the start.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 210 months is above that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2009
First posted
Jun 11, 2009
StartActual
Jun 9, 2009
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00918775
Responsible party
Sponsor
First posted
Jun 11, 2009
Start date
Jun 9, 2009
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Eric Jonasch
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion